Challenges in the evaluation and licensing of new pneumococcal vaccines, 7–8 July 2008, Ottawa, Canada

Feavers, Ian M.; Knežević, Ivana; Powell, Megan; Griffiths, Elwyn

doi:10.1016/j.vaccine.2009.03.087

Cited by 58 publications

(35 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Differences in OPA titers may reflect variability not only in the quantity but also in the quality of the antibodies elicited by different conjugates. These results highlight the necessity of using OPA assays in addition to the reference ELISA recommended by WHO when one is evaluating immune responses induced by candidate PCVs (12,50).…”

Section: Discussionmentioning

confidence: 96%

Impact of the Conjugation Method on the Immunogenicity of Streptococcus pneumoniae Serotype 19F Polysaccharide in Conjugate Vaccines

Poolman

Frasch

Nurkka

et al. 2011

Clin Vaccine Immunol

View full text Add to dashboard Cite

We found that conjugation of the serotype 19F polysaccharide using reductive amination (as in 7vCRM) resulted in the formation of at least one additional epitope that is not present in the native form of the 19F polysaccharide or following 19F conjugation using a bifunctional spacer (as in the prototype vaccine 7vOMPC) or cyanylation (as in PHiD-CV). We also found that pneumococcal vaccines conjugated using cyanylation induce more opsonophagocytic antibodies against serotype 19F and a considerably higher level of cross-opsonophagocytic antibodies against serotype 19A than vaccines conjugated using reductive amination. In conclusion, these results suggest that the conjugation method can influence the functionality of the antibodies induced against the homologous serotype 19F and the cross-reactive serotype 19A of S. pneumoniae. 7vCRM (Prevenar/Prevnar; Pfizer, Inc.) contains capsular polysaccharides of Streptococcus pneumoniae serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F, each conjugated to the nontoxic cross-reacting mutant diphtheria toxin CRM 197 . Serotype 19A was not included in 7vCRM, because it was expected that the immunological similarities with vaccine serotype 19F would elicit sufficient cross-protection, as observed for serotype 6B and the related serotype 6A (26,38,48,52). Serotypes 19F and 19A are indeed closely related biochemically (38, 52). Serotype 19A and 19F polysaccharides are composed of similar trisaccharide units polymerized through phosphate diester groups and differ only in the position of the linkage to the ␣-L-rhamnose residue: ␣(132) for 19F and ␣(133) for 19A (19,29

show abstract

Section: Discussionmentioning

confidence: 96%

Impact of the Conjugation Method on the Immunogenicity of Streptococcus pneumoniae Serotype 19F Polysaccharide in Conjugate Vaccines

Poolman

Frasch

Nurkka

et al. 2011

Clin Vaccine Immunol

View full text Add to dashboard Cite

show abstract

“…It is anticipated that the licensing of future pneumococcal conjugate vaccines for protection against IPD in children will require only immunogenicity data rather than efficacy data because placebo-controlled trials are not possible and very large studies would need to be done to show differences in the incidence of IPD between vaccines differing by only a few serotypes. (28,29) Immunogenicity A review of the serologic correlates of protection from IPD that are used to assist in the interpretation of immunogenicity studies is provided in a recent NACI statement. (4) More than 3000 children have received PNEU-C-13 in trials comparing PNEU-C-7 to PNEU-C-13, and assessing the immune response to concurrently administered vaccines in routine childhood vaccination schedules.…”

Section: Efficacymentioning

confidence: 99%

Update on the Use of Conjugate Pneumococcal Vaccines in Childhood

Desai¹,

McGeer²,

Quach-Thanh³

et al. 2010

Canada Communicable Disease Report

View full text Add to dashboard Cite

“…IgG-binding antibodies directed to the capsular polysaccharide, and the associated functional activity of these antibodies assessed by opsonophagocytosis assays (OPAs), are immunological correlates of protection. Accordingly, the recommendations of the WHO issued in the technical report series [8] and the update of this technical report [9] were used for licensing of PCV13.…”

mentioning

confidence: 99%

Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine: Emerging Data From Invasive Pneumococcal Disease, Pneumonia, Acute Otitis Media and Nasopharyngeal Carriage

Райнерт¹,

Тайши²

2012

Pediatr. farmakol.

View full text Add to dashboard Cite

A new WHO position paper has been published recently stressing the high priority of the inclusion of PCVs in childhood immunization programs worldwide.Planning for national use of pneumococcal vaccines should take besides other factors the distribution of pneumococcal serotypes in different age groups into consideration. In addition to the serotypes included in PCV7, PCV13 contains serotypes 1, 3, 5, 6A, 7F and 19A and this vaccine

show abstract

Challenges in the evaluation and licensing of new pneumococcal vaccines, 7–8 July 2008, Ottawa, Canada

Cited by 58 publications

References 11 publications

Impact of the Conjugation Method on the Immunogenicity of Streptococcus pneumoniae Serotype 19F Polysaccharide in Conjugate Vaccines

Impact of the Conjugation Method on the Immunogenicity of Streptococcus pneumoniae Serotype 19F Polysaccharide in Conjugate Vaccines

Update on the Use of Conjugate Pneumococcal Vaccines in Childhood

Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine: Emerging Data From Invasive Pneumococcal Disease, Pneumonia, Acute Otitis Media and Nasopharyngeal Carriage

Contact Info

Product

Resources

About